Page de couverture de The Lancet Infectious Diseases in conversation with

The Lancet Infectious Diseases in conversation with

The Lancet Infectious Diseases in conversation with

Auteur(s): The Lancet Group
Écouter gratuitement

À propos de cet audio

Saleha Hassan, Senior Editor at The Lancet Infectious Diseases, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from polio eradication in Africa to COVID-19 vaccines in Hong Kong, the treatment of early syphilis in adults to Mpox in the UK, and more.

© 2025 The Lancet Group Hygiène et mode de vie sain Science Sciences biologiques Troubles et maladies
Épisodes
  • Lilian Tina Minja and Norbert Heinrich on TB drug development

    Lilian Tina Minja and Norbert Heinrich on TB drug development
    Jul 9 2025

    Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment.

    Read the trials:

    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf

    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00289-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Voir plus Voir moins
    30 min
  • Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile

    Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile
    Jun 10 2025

    Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond.

    Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00233-6/fulltext?dgcid=buzzsprout_icw_podcast_10-06-25_laninf

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Voir plus Voir moins
    15 min
  • Jan Felix Drexler and Fernando Bozza on Oropouche virus

    Jan Felix Drexler and Fernando Bozza on Oropouche virus
    Apr 14 2025

    Jan Felix Drexler and Fernando Bozza discuss their recent study published in the journal— “The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America” and its wider implications for Oropouche virus and other arboviruses transmission, expansion, surveillance, and control.

    Read the full article:

    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00110-0/fulltext?dgcid=buzzsprout_icw_podcast_14-04-25_laninf

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Voir plus Voir moins
    35 min

Ce que les auditeurs disent de The Lancet Infectious Diseases in conversation with

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.